최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기한국임상약학회지 = Korean journal of clinical pharmacy, v.20 no.3, 2010년, pp.200 - 204
The purpose of this study was to investigate the effect of ticlopidine on the pharmacokinetics of nimodipine in rats. Pharmacokinetic parameters of nimodipine were determined in rats after oral administration of nimodipine (16 mg/kg) with or without ticlopidine (3 or 10 mg/kg). Ticlopidine inhibited...
* AI 자동 식별 결과로 적합하지 않은 문장이 있을 수 있으니, 이용에 유의하시기 바랍니다.
핵심어 | 질문 | 논문에서 추출한 답변 |
---|---|---|
칼슘채널차단제는 어떻게 신장 혈압을 낮추는가? | 칼슘채널차단제는 혈관이완작용이 있어 고혈압, 협심증 및 부정맥 치료에 널리 사용하고 있다.1) 이 약물들은 혈청 중 세포외액에 있는 칼슘이 심근세포와 혈관 평활근 세포막을 통과하는 통로를 차단하고 심장근육과 혈관평활근의 수축과정을 차단하여 심장 수축력을 감소시키고, 전신의 동맥과 관상동맥을 이완시키며, 또한 신혈관을 이완하여 신장으로 혈액 유입을 증가시키고 사구체 여과율과 나트륨 배설을 증가시켜 신장 혈압을 저하시킨다.2) | |
니모디핀이란 무엇인가? | 니모디핀 (nimodipine)은 1,4-dihydropyridine계 칼슘채널차단제로3) 지용성 약물이며 경구투여 시 신속하게 흡수되나 초회통과효과로 인해 생체이용률이 낮고 97-99% 단백결합을 하며, 빠르게 조직과 기관에 분포된다.4-5) 니모디핀은 간과 장관강막에 존재하는 cytochrome P450 (CYP)3A4에 인하여 산화되어 pyridine 대사체로 대사된다. | |
티클로피딘이란 무엇인가? | 티클로피딘은 데오필린과 안티피린 등과 같이 간의 cytochrome P-450 효소계에 의해 대사되는 여러 약제를 억제하는 중요한 원인으로 알려진 항혈소판제이다. 예를 들어 티크로피딘과 와파린을 함께 복용하였을 때 와파린 농도가 유의하게 증가하게 되었다. |
Scholz H. Pharmacological aspects of calcium channel blockers. Cardiovasc. Drugs Ther 1997; 10: 869-872.
Epstein M, Loutzenhister RD. Effects of calcium antagonists on renal hemodynamics. Am J Kidney Dis 1990; 16: 10-14.
Kazda S, Garthoff B, Krause HP, et al., Cerebrovascular effects of the calcium antagonistic dihydropyridine derivative nimodipine in animal experiments. Arzneimittelforschung 1982; 32: 331-338.
Maruhn D, Siefert HM, Weber H, et al., Pharmacokinetics of nimodipine. I. communication: absorption, concentration in plasma and excretion after single administration of [ $^{14}C$ ] nimodipine in rat, dog and monkey. Arzneimittelforschung 1985; 35: 1781-1786.
Suwelack D, Weber H, Maruhn D. Pharmacokinetics of nimodipine, II. communication: absorption, concentration in plasma and excretion after single administration of [ $^{14}C$ ] nimodipine in rat, dog and monkey. Arzneimittelforschung 1985; 35: 1787-1794.
Ramsch KD, Ahr G, Tettenborn D, et al., Overview on pharmacokinetics of nimodipine in healthy volunteer and in patients with subarachnoid hemorrhage. Neurochirurgia 1985; 28: 74-78.
Scherling D, Buhner K, Krause HP, et al., Biotransformation of nimodipine in rat, dog and monkey. Arzneimittelforschung 1991; 41: 392-398.
Guengerich FP, Brian WR, Iwasaki M, et al., Oxidation of dihydropyridine calcium channel blockers and analogues by human liver cytochrom P-450IIIA4. J Med Chem 1991; 34: 1834-1844.
Fuhr U, Maier-Bruggemann A, Blume H, et al., Grapefruit juice increases oral nimodipine bioavailability. Int J Clin Pharmacol Ther 1998; 36: 126-132.
Zhang L, Liu XD, Xie L, et al., P-glycoprotein restricted transport of nimodipine across blood-brain barrier. Acta Pharmacol Sin 2003; 24: 903-906.
Saltiel E, Ward A. Ticlopidine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutics efficacy in platelet-dependent disease states. Drugs 1987; 34: 222-262.
Gent M, Blakely JA, Easton JD, et al., The Canadian American ticlopidine study(CATS) in thromboembolic stroke. Lancet 1989; 1: 1215-1220.
Hass Wk, Easton JD, Adams HP, et al., A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. N Eng J Med 1989; 321: 501-507.
Janzon L, Bergqvist D, Boberg J, et al., Prevention of myocardial infarction and stroke in patients with intermittent claudication; effects of ticlopidine. Results from STIMS, the Swedish Ticlopidine Multicentre Study. J Intern Med 1990; 227: 301-308.
Haynes RB, Sandler RS, Larson EB, et al., A critical appraisal of ticlopidine, a new antiplatelet agent. Effectiveness and clinical indications for prophylaxis of atherosclerotic events. Arch Intern Med 1998; 152: 1376-1380.
Ito MK, Smith AR, Lee ML. Ticlopidine: a new platelet aggregation inhibitors. Clin Pharm 1992; 11: 603-617.
Verhaeghe R. Prophylactic antiplatelet therapy in peripheral arterial disease. Drugs 1991; 42: 51-57.
Solomon DH, Hart RG. Antithrombotic therapies for stroke prevention. Cur Opin Neurol 1994; 7: 48-53.
Buur T, Larsson R, Berglund U, et al., Pharmocokinetics and effect of ticlopidine on platelet aggregation in subjects with normal and impaired renal function. J Clin Pharmacol 1997; 37: 108-115.
Ko JW, Desta Z, Soukhova NV, et al., In vitro inhibition of the cytochrome P450 (CYP450) system by the antiplatelet drug ticlopidine: potent effect on CYP2C9 and CYP2D6. Br J Clin Pharmacol 2000; 49: 343-351.
Gidal BE, Sorkness CA, McGill KA, et al., Evaluation of a potential enantioselective interaction between ticlopidine and warfarin in chronically anticoagulated patients. Ther Drug Monit 1995; 17: 33-38.
Shah J, Fratis A, Ellis D, et al., Effect of food and antacid on absorption of orally administered ticlopidine hydrochloride. J Clin Pharmacol 1990; 30: 733-736.
Qian M, Gallo JM. High-perfomance liquid chromatographic determinination of the calcium channel blocker nimodipine in monkey plasma. J Chromatogr 1992; 578: 316-320.
Mc Donnell CG, Shorten G, Van Pelt FN. Effect of atorvastatin and fluvastatin on the metabolism of midazolam by cytochrome P450 in vitro. Anaesthesia 2005; 60: 747-753.
Choi DH, Lee IG, Choi JS. Pharmacokinetic interaction between fluvastatin and nicardipine. Kor J Clin Pharm 2007; 17: 65-69.
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.